Afatinib for the treatment of metastatic non-small cell lung cancer

Targeting the epidermal growth factor receptor (EGFR) in patients with non-small cell lung cancer (NSCLC) harboring sensitizing mutations in the tyrosine kinase (TKI) domain has led to a significant change in the management of this disease. The classic or sensitizing mutations are G719X mutation in...

Descripción completa

Detalles Bibliográficos
Autores principales: Joshi, Monika, Rizvi, Syed M, Belani, Chandra P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340466/
https://www.ncbi.nlm.nih.gov/pubmed/25733926
http://dx.doi.org/10.2147/CMAR.S51808

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4340466/
https://www.ncbi.nlm.nih.gov/pubmed/25733926
http://dx.doi.org/10.2147/CMAR.S51808

Ejemplares similares